Death & DyingHeart / Stroke-RelatedHeart Attack Heart / Stroke-RelatedHigh Blood Pressure Heart / Stroke-RelatedStroke Heart / Stroke-RelatedDrugsDrugs Heart AttackHeart AttackHigh Blood PressureStrokeCardiovascular DiseasesHeart Attack DrugsGeneral HealthDeath
Updated on July 26, 2022
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Nov. 5, 2004 (HealthDayNews) -- Atenolol, a drug commonly prescribed to treat hypertension, doesn't prevent heart attacks or cardiovascular death any better than dummy drugs and is less effective than a wide variety of other blood pressure medications, a new study finds.
Not only should atenolol not be used to treat high blood pressure, it should not be used as a control drug to test other blood pressure drugs as it has been, researchers cautioned.
"We looked at all studies where atenolol is a first-line drug," said lead researcher Dr. Bo Carlberg from the Umea University Hospital in Sweden.
Carlberg's team reviewed four studies that compared atenolol, which belongs to a class of drugs called beta blockers, with a placebo. In these studies, there were a total of 6,825 patients, who were followed up for an average of four to six years. During that time, the researchers looked for death by any cause, cardiovascular death, heart attacks or stroke.
Atenolol was effective in lowering blood pressure. However, "Compared with placebo, atenolol did not decrease the risk of death of any kind, did not reduce the risk of cardiovascular death, did not reduce the risk of heart attack, but showed a clear, but not significant, tendency in reducing the frequency of stroke," Carlberg said.
The investigators also reviewed five studies comparing atenolol with other blood pressure drugs, including diuretics, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and the angiotensin II antagonist, losartan.
In these studies, atenolol appeared to be not as good as these other drugs in preventing death, Carlberg said.
The report appears in the Nov. 6 issue of The Lancet.
Whether other beta blockers are as ineffective as atenolol is not known, Carlberg noted. "Our hypothesis is that atenolol is different from other beta blockers," he said. Carlberg doesn't believe other beta-blockers have the same problem as atenolol.
"Atenolol is a widely used drug," Carlberg said. "But the documentation about its effects on cardiovascular disease is weak. We suggest that it shouldn't be a first-line drug. There are many more effective antihypertensive drugs with much better documentation."
Carlberg added that atenolol should not be used as a reference drug in clinical studies, because it can make the test drug look more effective than it may really be.
"We don't promote atenolol," said Gary Burell, a spokesman for AstraZeneca Pharmaceuticals, which makes atenolol under the brand name Tenormin. "Atenolol has been out for a number of years, and you get new and improved molecules like Toprol-XL that show advantages over earlier drugs."
Toprol-XL is a new beta blocker that is being promoted by AstraZeneca for treating high blood pressure.
Burell noted that because atenolol is available as a generic drug, AstraZeneca no longer actively promotes it, although it still manufactures the drug. "There is no problem with atenolol," he said. "But there are no trials that show benefits that are seen with newer beta blockers like Toprol-XL."
The review "is a reminder that medical care can never be complacent," said Dr. David L. Katz, director of the Prevention Research Center at Yale University School of Medicine. "Atenolol is a drug long used in the treatment of hypertension. But since its introduction, many new drugs have come along, and some old drugs have been assessed in new ways."
Katz noted that rarely does a single paper warrant abrupt change in clinical practice. "But clinicians and researchers alike must keep their practice in line with the most current evidence," he added. "By this standard, it is indeed probable that atenolol is overused, and that the tailored selection of antihypertensive therapy can, and should, be improved."
The American Heart Association can tell you more about high blood pressure.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Read this Next
Other Trending Articles